[Market Focus] Voronoi Hits Record High on News of Proven Efficacy in Treating Brain Metastasis Patients

Voronoi is showing strong gains in early trading.

As of 9:03 a.m. on October 24, Voronoi was trading at 190,000 won, up 11.50% (19,600 won) from the previous day. During the session, the price surged to 194,900 won, setting a new 52-week high.

Investor sentiment appears to have been boosted by news that Voronoi's non-small cell lung cancer drug candidate 'VRN11' has demonstrated excellent therapeutic efficacy in patients with brain metastases.

On October 23 (local time), Voronoi announced at the international cancer conference 'AACR-NCI-EORTC 2025' that a partial response (PR), defined as a tumor reduction of more than 30%, was observed in 3 out of 4 patients with non-small cell lung cancer resistant to EGFR (epidermal growth factor receptor) targeted therapies, specifically those with the C797S mutation. The disease control rate (DCR) was also confirmed in all 11 patients with brain metastases (BM) or leptomeningeal metastases (LM).

No grade 3 or higher severe adverse events were reported among 54 patients up to a 400 mg dose, and excellent tolerability was maintained even in patients treated for more than 10 months, indicating positive safety results. Based on these findings, Voronoi plans to conduct a phase 1b/2 cohort study targeting patients with the EGFR C797S mutation.